Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Results Our comprehensive search yielded 5 eligible studies. Using the Cochrane risk-of-bias tool, overall, we judged all 5 studies to be at high risk of bias. While all studies reported a statistically significant difference between B. monnieri and the comparator in at least one outcome, we rated the overall quality of evidence for the Alzheimer's Disease Assessment Scale-Cognitive Subscale, Postgraduate Institute Memory Scale, Mini-Mental State Examination, and Wechsler Memory Scale to be very low due to downgrading by 2 levels for high risk of bias and 1 more level for impreciseness due to small sample sizes and wide CIs.

What this study adds

Evidence grade: High

This is a narrative review. This review of five randomized trials found all of them were at high risk of bias, and the overall quality of evidence for the cognitive measures was rated very low. Because of this, the evidence is not strong enough to show that Bacopa monnieri helps treat dementia due to Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Basheer, A., Agarwal, A., Mishra, B., Gupta, A., Padma Srivastava, M. V., Kirubakaran, R., et al. (2022). Use of Bacopa monnieri in the Treatment of Dementia Due to Alzheimer Disease: Systematic Review of Randomized Controlled Trials. Interactive journal of medical research. https://doi.org/10.2196/38542

Vancouver

Basheer A, Agarwal A, Mishra B, Gupta A, Padma Srivastava MV, Kirubakaran R, et al. Use of Bacopa monnieri in the Treatment of Dementia Due to Alzheimer Disease: Systematic Review of Randomized Controlled Trials. Interactive journal of medical research. 2022. doi:10.2196/38542. PMID: 35612544.

BibTeX

@article{basheer2022-35612544,
  author  = {Basheer, A. and Agarwal, A. and Mishra, B. and Gupta, A. and Padma Srivastava, M. V. and Kirubakaran, R. and Vishnu, V.},
  title   = {{Use of Bacopa monnieri in the Treatment of Dementia Due to Alzheimer Disease: Systematic Review of Randomized Controlled Trials}},
  journal = {Interactive journal of medical research},
  year    = {2022},
  doi     = {10.2196/38542},
  pmid    = {35612544},
  url     = {https://doi.org/10.2196/38542}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This review of five randomized trials found all of them were at high risk of bias, and the overall quality of evidence for the cognitive measures was rated very low. Because of this, the evidence is not strong enough to show that Bacopa monnieri helps treat dementia due to Alzheimer's disease.

Study details

How this study scored 43/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 1 of 2; Times cited 3 of 7; Citations per year 2 of 5; Impact for its field and year 2 of 6; Cited by studies here 1 of 6; Still being cited 2 of 4; Senior author's track record 2 of 4; Institution's track record 0 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 43 of 100.43 of 100 points earned57 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and studied in people because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Interactive journal of medical research)
Journal's citation record 0 / 4 Interactive Journal of Medical Research: journal h-index 48 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2022 — within 6 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 1 / 2 Randomized (as stated in the record)
Times cited 3 / 7 Cited 32 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 5.3 citations a year over 6 year(s) since 2022
Impact for its field and year 2 / 6 Cited 2.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 2 other studies in this library
Still being cited 2 / 4 Cited 27 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Venugopalan Y. Vishnu: h-index 23 (OpenAlex, whole career)
Institution's track record 0 / 3 All India Institute of Medical Sciences: institution h-index 440 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 35612544)
Free to read 2 / 2 Free to read
Total 43 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Treatments from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →